A particularly promising cancer treatment is the use of monoclonal antibodies (mAbs)
against immune checkpoints (ie, immune checkpoint inhibitors; ICIs). However, many …

While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry
has been shown to be an imperfect biomarker that only applies to a limited number of …

Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC)
with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in …

Background Accelerated approval (AA) of novel anticancer drugs based on surrogacy has
attracted considerable concern globally. China National Medical Products Administration …

Background Long intergenic non-protein coding RNA 1140 (LINC01140), a long non-coding
RNA, is highly expressed in various cancers; however, its biological functions in lung cancer …

The nutritional status has the potential to affect cancer immunity. We evaluated the
relationship between the nutritional status and the efficacy of nivolumab in patients with non …

Background Lipids have immunomodulatory functions and the potential to affect cancer
immunity. Methods The associations of pretreatment serum cholesterol and long-chain fatty …

Introduction Programmed death-ligand 1 (PD-L1) copy number gains may be predictive of
clinical response to immunotherapy in NSCLC. This study investigated PD-L1 copy number …

To improve the treatment strategy of immune‑checkpoint inhibitors for non‑small cell lung
cancer (NSCLC), a comprehensive analysis of programmed death‑ligand (PD‑L) 1 and PD …

Recent cancer immunotherapy development with immune checkpoint inhibitors has shown
durable clinical responses in a wide variety of tumor types. These drugs targeting …